CompletedPhase 2NCT04186000
Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Universiteit Antwerpen
- Principal Investigator
- Hypolite Mavoko Muhindo, Dr.University of Kinshasa, Tropical Medicine Department
- Intervention
- Ad26.ZEBOV vaccine(biological)
- Enrollment
- 699 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (1)
- Hôpital Général de Référence de Boende, Boende, Province de La Tshuapa, Democratic Republic of the Congo
Collaborators
Johnson & Johnson · Ace Africa · Innovative Medicines Initiative · Coalition for Epidemic Preparedness Innovations · University of Kinshasa
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04186000 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT05992480REVIVE (Response to the Ebola Virus Vaccine)Tulane University
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University